New in Open Access in 2020
Leading Medicine and Health Journals
Looking to place your work in a leading open access journal?
Taylor & Francis has an interdisciplinary medicine and health portfolio that's accessible to a worldwide network of authors, readers, policymakers and professionals. Our journals publish high impact research helping to improve health and disease treatment.
We publish 55+ open access medicine and health journals, and we're so proud to announce that in 2020 we'll have added three more!
Open access at Taylor & Francis is made simple for authors. Each journal has information for authors, specific to that journal's requirements and features, like format-free submissions, a new feature that allows the author to submit their manuscript, no formatting necessary. We provide a peer review process that will validate your research, and publish the best version of your manuscript — a task that only quality editors and peer reviewers can be trusted with. Browse the newest open access titles below and find out more about each journal by clicking-through to the Aims & Scope.
New in Open Access
Health Systems & Reform
Now indexed in MEDLINE
Aging, chronic diseases, persistent infectious diseases, and new healthcare technologies are among mounting challenges that require innovative and cost-effective approaches to healthcare delivery and reform. HS&R is dedicated to catalyzing cross-national knowledge transfer and translation in health systems and reform. The journal’s mission is to create a global platform for sharing cutting edge knowledge, skills and lessons in health systems and reform and for leaders, professionals and students. Most importantly, HS&R will contribute to strengthening health systems and to improving care delivered to patients.
2018 Impact Factor: 4.405
A multi-disciplinary journal dedicated to the art and science of antibody research and development. mAbs has a strong scientific and medical focus, which strives to serve a broader readership of scientists, clinical researchers, and physicians, as well as the wider mAb community, including our readers involved in technology transfer, legal issues, investment, strategic planning and the regulation of therapeutics.
2018 Impact Factor: 5.333
This high-profile journal focuses exclusively on tumor immunology.
Recent progress has allowed for the first clinical demonstration (and FDA approval) of anticancer immunotherapies. As a result, immunological biomarkers are becoming ever more important to determine the prognosis of cancers and to predict the efficacy of chemotherapies. There is also a strong rationale in favor of combining conventional anticancer therapies with immunotherapies. OncoImmunology serves as a platform for groundbreaking research that's making an impact.